Filing Flows › Abeona Therapeutics (ABEO) › Q3 2026 › vs Q2 2026
Abeona Therapeutics (ABEO) Q3 2026 vs Q2 2026 (quarter over quarter)
Abeona Therapeutics's revenue rose $2.1M (+19%) from $11.4M in Q2 2026 to $13.5M in Q3 2026.
Abeona Therapeutics, Q3 2026: revenue $13.5M, operating margin -96.4%, net loss $4.8M, operating cash flow −$8.3M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $13.5M | $11.4M | $2.1M | +19% |
| Other income, net | $8.2M | −$6.5M | $14.7M | — |
| Net loss | $4.8M | $20.2M | −$15.4M | -76% |
| Costs & expenses | $26.5M | $31.6M | −$5.1M | -16% |
| Operating costs | $26.5M | $25.0M | $1.5M | +6% |
| Income tax | $18K | $0 | $18K | — |
| Cost of revenue | $5.7M | $4.2M | $1.5M | +37% |
| Research & development | $3.7M | $5.0M | −$1.3M | -27% |
| SG&A | $17.1M | $15.8M | $1.3M | +8% |
| Operating cash sources | $11.8M | $21.5M | −$9.7M | -45% |
| Depreciation & amortization | $705K | $665K | $40K | +6% |
| Share-based compensation | $2.8M | $3.4M | −$584K | -17% |
| Cash used in operations | $8.3M | $17.5M | −$9.2M | -53% |
| Net loss absorbed | $4.8M | $20.2M | −$15.4M | -76% |
| Working capital & other | $7.0M | $1.3M | $5.7M | +422% |
Questions
How much did Abeona Therapeutics's revenue grow quarter over quarter in Q3 2026?
Abeona Therapeutics's revenue rose $2.1M (+19%) from $11.4M in Q2 2026 to $13.5M in Q3 2026.